Partition Dosimetry and Outcomes of Metastatic Neuroendocrine Tumors after Yttrium-90 Resin Microsphere Radioembolization

Abstract

Purpose

To characterize estimated mean tumor-absorbed dose (AD_T) and objective response of metastatic neuroendocrine tumor (NET) after resin microsphere yttrium-90 (⁹⁰Y) hepatic radioembolization using partition dosimetry.

Materials and Methods

In this retrospective, single-center study, multicompartment dosimetry of index tumors receiving ⁹⁰Y radioembolization between 2013 and 2022 involved the use of Sureplan (MIM Software, Cleveland, Ohio) and technetium-99m macroaggregated albumin single photon emission computed tomography (SPECT) combined with computed tomography. Thirty-six patients with NET underwent treatment of 56 index tumors. Patients underwent imaging every 3–6 months after treatment to determine best response per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and modified RECIST (mRECIST) criteria. Responses were categorized as objective response (OR) or nonresponse (NR). Wilcoxon rank sum test evaluated differences in continuous variables, and Pearson χ² test evaluated differences in categorical variables.

Results

Median follow-up was 582 days (IQR, 187–1,227 days). Per RECIST 1.1, 27 patients (75%) experienced OR and 9 patients experienced (25%) NR. Of the 36 patients, 33 (92%) showed hypervascular, mRECIST-evaluable tumors. Among them, 28 patients (85%) showed mRECIST OR and 5 patients (15%) showed NR. The mRECIST OR group received a higher AD_T than the NR group (median, 107 Gy; IQR, 95.1–154 Gy vs median, 70.4 Gy; IQR, 62.9–87.6 Gy; P = .048). All tumors receiving at least 120 Gy showed mRECIST OR.

Conclusions

In hypervascular metastatic NET treated by ⁹⁰Y resin microsphere radioembolization, higher tumor dose was associated with better tumor response per mRECIST. Doses of ≥120 Gy led to OR.